{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:01:26Z","timestamp":1772748086597,"version":"3.50.1"},"reference-count":78,"publisher":"Informa UK Limited","issue":"15","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2016,10,12]]},"DOI":"10.1080\/14656566.2016.1232387","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T06:03:39Z","timestamp":1473660219000},"page":"2097-2106","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Abacavir + dolutegravir + lamivudine for the treatment of HIV"],"prefix":"10.1080","volume":"17","author":[{"given":"Laura","family":"Comi","sequence":"first","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2015. Available from: http:\/\/aidsinfo.nih.gov\/guidelines."},{"key":"e_1_3_3_4_1","unstructured":"EACS: European AIDS Clinical Society. Guidelines version 8 0. [cited Oct 2015]. Available from: http:\/\/eacsociety.org."},{"key":"e_1_3_3_5_1","unstructured":"Williams DI Churchill D Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Available from: http:\/\/www.bhiva.org\/documents\/Guidelines"},{"key":"e_1_3_3_6_1","unstructured":"World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection second edition. [cited 2016 Jun]. Available from: http:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-11-201206050-00419"},{"issue":"3","key":"e_1_3_3_8_1","first-page":"168","article-title":"Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment","volume":"14","author":"Llibre JM","year":"2012","unstructured":"Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14(3):168\u2013178.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku279"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182282cfc"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir505"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08158-8"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60423-7"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/649897"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00751.x"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.197"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830fe35e"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819ff0e6"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq244"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31826f993c"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.05.015"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012080857"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.01.022"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601005"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.073189"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0256-y"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00010"},{"key":"e_1_3_3_31_1","unstructured":"ViiV Healthcare UK Ltd. Triumeq 50 mg\/600 mg\/300 mg filmcoated tablets: EU summary of product characteristics. 2014. [cited 2015 Feb 9]. Available from: http:\/\/www.ema.europe.eu."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-10"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328356db89"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku095"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000193"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00842-09"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70290-0"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1708"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05739-11"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu477"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2665"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829ed7a4"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2504-2506.2005"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00292-13"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"e_1_3_3_49_1","unstructured":"Weller S Borland J Wynne B et al. Effect of carbamazepine on dolutegravir pharmacokinetics. ICAAC; 2014 Sep 5\u20139; Washington DC. Poster H-1013."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr139"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000983","article-title":"The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects","author":"Song IH","year":"2016","unstructured":"Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72:400\u2013407.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"e_1_3_3_54_1","unstructured":"Pappa K Baumgarten A Felizarta F et al. Dolutegravir (DTG) + abacavir\/lamivudine once daily superior to tenofovir\/emtricitabine\/efavirenz in treatment na\u00efve HIV subjects: 144-week results from SINGLE (ING114467). Poster presented at: Annual Interscience Conference of Antimicrobial Agents and Chemotherapy; 2014 Sep 5\u20139; Washington DC."},{"issue":"1","key":"e_1_3_3_55_1","first-page":"261","article-title":"Dolutegravir regimen statistically superior to tenofovir\/emtricitabine\/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]","volume":"22","author":"Walmsley S","year":"2014","unstructured":"Walmsley S, Berenguer J, Khuong-Josses MA. Dolutegravir regimen statistically superior to tenofovir\/emtricitabine\/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]. Top Antivir Med. 2014;22(e\u20131):261\u2013262.","journal-title":"Top Antivir Med"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"issue":"4","key":"e_1_3_3_58_1","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.7448\/IAS.17.4.19490","article-title":"Once-daily dolutegravir is superior to once-daily darunavir\/ritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week results from FLAMINGO","volume":"17","author":"Molina JM","year":"2014","unstructured":"Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir\/ritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17(4Suppl 3):19490.","journal-title":"J Int AIDS Soc"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_3_60_1","unstructured":"Trottier B Lake J Logue K et al. Switching to abacavir\/dolutegravir\/lamivudine fixed dose combination (ABC\/DTG\/3TC FDC) from a PI INI or NNRTI based regimen maintains HIV suppression. Program and abstracts of the 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 2015 Sep 17\u201321; San Diego CA."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1505-199"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105653"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04440.x"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_3_65_1","unstructured":"Cahn P Figueroa MI Sued O et al. Dolutegravir-lamivudine as initial therapy in HIV-infected ARV naive patients: first results of the PADDLE trial. Abstract:1066 presented at EACS; 2015 Oct 21\u201324; Barcelona"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw147"},{"key":"e_1_3_3_67_1","unstructured":"Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects. Clinical Trials Gov. 2015. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02373930?term=RPV+DTG&rank=1."},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv430"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw078"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw011"},{"key":"e_1_3_3_71_1","unstructured":"Safety and efficacy of GS-9883 \u00b1 emtricitabine\/tenofovir alafenamide versus dolutegravir \u00b1 emtricitabine\/tenofovir alafenamide in HIV-1 infected antiretroviral treatment-naive adults. Clinical Trials Gov. 2015. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02397694?term=GS-9883&rank=1."},{"key":"e_1_3_3_72_1","unstructured":"Margolis A Gonz\u00e1lez-Garc\u00eda J Stellbrink HJ et al. Cabotegravir+rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. Presented at CROI; 2016 Feb 22\u201325."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu221"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1202-71"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181a572cf"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0024-z"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s10330"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003028"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S49428"},{"issue":"1","key":"e_1_3_3_80_1","first-page":"69","article-title":"Optimal terapy of HIV\/HCV coinfected patients with direct acting antivirals JK Rockstroh","volume":"34","author":"Rockstroh JK","year":"2014","unstructured":"Rockstroh JK. Optimal terapy of HIV\/HCV coinfected patients with direct acting antivirals JK Rockstroh. Liver Int. 2014;34(Suppl. 1):69\u201378.","journal-title":"Liver Int"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2016.1232387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:02:06Z","timestamp":1772744526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2016.1232387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":78,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,10,12]]}},"alternative-id":["10.1080\/14656566.2016.1232387"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2016.1232387","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}